The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) has launched a new observational study that will gather data on patients with primary and secondary liver tumours treated with SIR‰ÛSpheres microspheres at specialist hospitals across Europe.
The CIRSE registry for SIR‰ÛSpheres Therapy (CIRT) has been designed to collect a large amount of data on the real‰Ûlife application of selective internal radiation therapy (SIRT), also known as radioembolization. Furthermore, the study collects extensive quality‰Ûof‰Ûlife data to learn more about the palliative aspect of SIR‰ÛSpheres microspheres. CIRT is a single‰Ûdevice registry that was developed by the society in collaboration with Sirtex Medical, the manufacturer of SIR‰ÛSpheres Y‰Û90 resin microspheres.
Previous research on SIR‰ÛSpheres microspheres has shown positive results in the treatment of liver cancer.
José Ignacio Bilbao, head of Interventional Radiology, Clínica Universidad de Navarra, Pamplona, Spain and chairman of the CIRT Steering Committee, said: “CIRSE is pleased to have developed the CIRT registry, which we believe will help the doctors who administer SIR‰ÛSpheres therapy to better understand the real‰Ûlife clinical application of SIR‰ÛSpheres microspheres throughout Europe”. He added that “our goal is to enter treatment data on over 500 patients a year from more than 20 specialist European hospitals into the new CIRT registry.”
